Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

INTRODUCTION: The purpose of this study was to determine whether maraviroc, a human CC chemokine receptor 5 (CCR5) antagonist, is safe and effective in the treatment of active rheumatoid arthritis (RA) in patients on background methotrexate (MTX). METHODS: This phase IIa study comprised two distinct...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleishaker, Dona L, Garcia Meijide, Juan A, Petrov, Andriy, Kohen, Michael David, Wang, Xin, Menon, Sujatha, Stock, Thomas C, Mebus, Charles A, Goodrich, James M, Mayer, Howard B, Zeiher, Bernhardt G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392799/
https://www.ncbi.nlm.nih.gov/pubmed/22251436
http://dx.doi.org/10.1186/ar3685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392799/
https://www.ncbi.nlm.nih.gov/pubmed/22251436
http://dx.doi.org/10.1186/ar3685

Ejemplares similares